MS Briefs

Multidisciplinary rehabilitation can improve highly impacting symptoms of relapse-onset MS


 

Key clinical point : The personalized multidisciplinary rehabilitation (PMDR) approach can improve highly impacting symptoms in patients with relapse-onset multiple sclerosis (MS) and have a positive influence on their quality of life.

Major finding : Patients receiving PMDR had a reduction in perceived fatigue and improvement of walking abilities and health-related quality of life compared with control individuals. Improved performance on a motor sequence learning task in terms of accuracy was observed after rehabilitation. All improvements persisted at the 4-week follow-up.

Study details : A longitudinal parallel group study included 24 patients with relapse-onset MS, who received a 4-week PMDR, and 24 control individuals.

Disclosures: The study was supported by the Swiss Multiple Sclerosis Society. Athina Papadopoulou, Laura Gaetano, Katrin Parmar, Thierry Ettlin, Corina Schuster-Amft, Jens Wuerfel, Ludwig Kappos, Till Sprenger, and Stefano Magon reported receiving research support/speaker fees/speaker honoraria/travel support/consultancy fees/advisory fees from one or more pharmaceutical companies and/or organizations. The remaining authors declared no conflict of interest.

Citation: Zuber P et al. J Neurol. 2020 Mar 2. doi: 10.1007/s00415-020-09768-6 .

Recommended Reading

Shared medical appointments educate and encourage MS patients
ICYMI Multiple Sclerosis
Hyperlipidemia occurs earlier in patients with MS
ICYMI Multiple Sclerosis
Age does not appear to affect efficacy of siponimod in secondary progressive MS
ICYMI Multiple Sclerosis
Serum GFAP may indicate disease severity in NMOSD
ICYMI Multiple Sclerosis
DMT use is common in older patients with MS
ICYMI Multiple Sclerosis
Manual dexterity may decline more rapidly in pediatric-onset MS
ICYMI Multiple Sclerosis
Teriflunomide increases the likelihood of achieving NEDA in relapsing-remitting MS
ICYMI Multiple Sclerosis
Sexual dysfunction is highly prevalent in women with MS
ICYMI Multiple Sclerosis
Elevated D-dimer after infusion of alemtuzumab in patients with MS
ICYMI Multiple Sclerosis
60% of morbidity comes from 30% of patients with moderate-to-severe MS
ICYMI Multiple Sclerosis